Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, 3010, Bern, Switzerland.
Department of Radiation Oncology, Stadtspital Triemli, Zurich, Switzerland.
Radiat Oncol. 2022 Aug 13;17(1):141. doi: 10.1186/s13014-022-02112-4.
Systemic inflammation is predictive of the overall survival in cancer patients and is related to the density of immune cells in the tumor microenvironment of cancer, which in turn correlates with F -fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) metabolic parameters (MPs). The density of tumor-infiltrating lymphocytes (TILs) in the microenvironment has the potential to be a biomarker that can be used clinically to optimize patient selection in oropharyngeal head and neck squamous cell carcinoma (HNSCC). There is little to no data regarding the association of systemic inflammation with PET/CT-MPs, especially in HNSCC. This study aimed to evaluate the correlation between markers of host inflammation, namely blood neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), with the PET/CT-MPs standardized uptake value (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the primary tumor, derived from FDG-PET/CT in patients with nonmetastatic (cM0) HNSCC before treatment. We hypothesized that NLR and PLR at baseline are positively correlated with PET/CT-MPs.
A retrospective review of consecutive patients with HNSCC with a pretreatment PET/CT was performed. NLR and PLR were computed using complete blood counts measured within 10 days before the start of any treatment. The correlation between NLR and PLR with PET/CT-MPs was evaluated with Spearman's rho test.
Seventy-one patients were analyzed. Overall survival (OS) at 1, 2, and 3 years was 86%, 76%, and 68%. PLR was found to be correlated with MTV (rho = 0.26, P = .03) and TLG (rho = 0.28, P = .02) but not with maximum SUV or mean SUV. There was no correlation between NLR and the analyzed PET/CT-MPs. TLG was associated with worse survival in uni- and multivariable analysis, but no other PET/CT-MPs were associated with either OS or disease-specific survival (DSS). NLR and PLR were associated with OS and DSS on uni- and multivariable analysis.
In patients with HNSCC before any treatment such as definitive radio (chemo)therapy or oncologic surgery followed by adjuvant RT, baseline PLR correlated with MTV and TLG but not with SUV. NLR was not correlated with any PET/CT-MPs analyzed in our study. Confirmatory studies are needed, and a potential interaction between tumor microenvironment, host inflammation, and FDG-PET/CT measures warrants further investigation.
全身炎症可预测癌症患者的总生存率,并与癌症肿瘤微环境中免疫细胞的密度相关,而肿瘤微环境中免疫细胞的密度又与 F-氟脱氧葡萄糖(FDG)-正电子发射断层扫描/计算机断层扫描(PET/CT)代谢参数(MPs)相关。肿瘤浸润淋巴细胞(TILs)在微环境中的密度有可能成为一种生物标志物,可用于临床优化口咽头颈部鳞状细胞癌(HNSCC)患者的选择。关于全身炎症与 PET/CT-MPs 的关联,特别是在 HNSCC 中,几乎没有数据。本研究旨在评估宿主炎症标志物(即血液中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR))与原发性肿瘤 FDG-PET/CT 的标准摄取值(SUV)、代谢肿瘤体积(MTV)和总肿瘤糖酵解(TLG)之间的相关性,这些参数源自治疗前未经转移(cM0)的 HNSCC 患者的 PET/CT。我们假设,基线时 NLR 和 PLR 与 PET/CT-MPs 呈正相关。
对连续接受 HNSCC 治疗前 PET/CT 检查的患者进行回顾性分析。在开始任何治疗前 10 天内通过全血细胞计数计算 NLR 和 PLR。使用 Spearman's rho 检验评估 NLR 和 PLR 与 PET/CT-MPs 的相关性。
共分析了 71 例患者。1、2 和 3 年的总生存率(OS)分别为 86%、76%和 68%。PLR 与 MTV(rho=0.26,P=0.03)和 TLG(rho=0.28,P=0.02)呈正相关,但与最大 SUV 或平均 SUV 无关。NLR 与分析的 PET/CT-MPs 之间没有相关性。TLG 在单变量和多变量分析中与较差的生存相关,但其他 PET/CT-MPs 与 OS 或疾病特异性生存率(DSS)均无关。NLR 和 PLR 在单变量和多变量分析中与 OS 和 DSS 相关。
在接受根治性放化疗或肿瘤切除术加辅助放疗等治疗前的 HNSCC 患者中,基线 PLR 与 MTV 和 TLG 相关,但与 SUV 无关。NLR 与本研究分析的任何 PET/CT-MPs 均不相关。需要进行确证性研究,并且肿瘤微环境、宿主炎症和 FDG-PET/CT 测量之间的潜在相互作用需要进一步研究。